Just when we thought we might be seeing the light at the end of the tunnel for the COVID-19 pandemic, a new Omicron variant was discovered in Africa. Although many countries shut down travel from Africa, it’s probably too late — it probably was being spread before the Omicron variant was found.
Like when the Delta variant was first observed, there was a lot of confusion about how serious it was going to be and whether vaccines would be effective. It caused a surge in cases and deaths worldwide over the summer.
Although it’s very early, I think there is enough information to, at a minimum, understand what may be upcoming. Of course, as with everything about this pandemic, stay tuned because what we know today may be superseded by what we discover tomorrow. Continue reading “Omicron variant of COVID — some initial facts about vaccines”
Pharmaceutical giants Pfizer and Merck have developed new COVID-19 drugs that could become a part of the tools used by physicians to treat COVID. Because of the importance of these drugs, both companies are seeking Emergency Use Authorizations (EUA) from the US FDA to get them in the hands of physicians as quickly as possible.
I have previously written about the Merck drug, molnupiravir, which will go by the trade name of Lagevrio. The Pfizer drug is called PF-07321332, with the trade name Paxlovid. Both drugs are purpose-developed anti-viral medications that have shown strong effectiveness against SARS-CoV-2, the virus that causes COVID-19. These are real antiviral drugs that were developed to treat COVID-19, unlike horse dewormers that have no effect against COVID-19.
This article will be in the form of a simple chart so that you can quickly see the advantages and disadvantages of both Pfizer and Merck COVID-19 drugs. I hope you find this helpful, and drop a note in the comments if you want me to add or change any information. Continue reading “Comparing COVID drugs from Pfizer and Merck — vaccines still critical”
Pharmaceutical giant Merck announced a new drug to treat COVID-19, called molnupiravir, which appeared to cut the risk of hospitalization and death by nearly half for at-risk patients. Furthermore, Merck will be seeking an emergency use authorization for it immediately.
Although this may sound like good news, and if you are reading the news about this drug, you’d think it was a miracle, I want to make sure that everyone understands several important factors about this drug’s safety and effectiveness profile. It is not a miracle, but it may be an important addition to the treatment protocols for COVID-19 patients, especially those at the highest risk of hospitalization or death.
This is not a worthless drug, at least for COVID-19, such as the horse dewormer, ivermectin, that has become popular with the pseudoscience crowd. Molnupiravir was designed from the beginning as an anti-viral drug. Continue reading “Merck seeking emergency us authorization for molnupiravir, new COVID-19 drug”